-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
E.Rodriguez--AT